Intermittent PTHrP(1–34) Exposure Augments Chondrogenesis and Reduces Hypertrophy of Mesenchymal Stromal Cells
Authors:
Open Access
- 17 May 2014
- journal article
- research article
- Published by SAGE Publications in Stem Cells and Development
- Vol. 23 (20) , 2513-2523
Abstract
Phenotype instability and premature hypertrophy prevent the use of human mesenchymal stromal cells (MSCs) for cartilage regeneration. Aim of this study was to investigate whether intermittent supplementation of parathyroid hormone-related protein (PTHrP), as opposed to constant treatment, can beneficially influence MSC chondrogenesis and to explore molecular mechanisms below catabolic and anabolic responses. Human MSCs subjected to chondrogenic induction in high-density culture received PTHrP(1–34), forskolin, dbcAMP, or PTHrP(7–34) either constantly or via 6-h pulses (three times weekly), before proteoglycan, collagen type II, and X deposition; gene expression; and alkaline phosphatase (ALP) activity were assessed. While constant application of PTHrP(1–34) suppressed chondrogenesis of MSCs, pulsed application significantly increased collagen type 2 ( COL2A1 ) gene expression and the collagen type II, proteoglycan, and DNA content of pellets after 6 weeks. Collagen type 10 ( COL10A1 ) gene expression was little affected but Indian hedgehog (IHH) expression and ALP activity were significantly downregulated by pulsed PTHrP. A faster response to PTHrP exposure was recorded for ALP activity over COL2A1 regulation, suggesting that signal duration is critical for catabolic versus anabolic reactions. Stimulation of cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA) signaling by forskolin reproduced major effects of both treatment modes, whereas application of PTHrP(7–34) capable of protein kinase C (PKC) signaling was ineffective. Pulsed PTHrP exposure of MSCs stimulated chondrogenesis and reduced endochondral differentiation apparently uncoupling chondrogenic matrix deposition from hypertrophic marker expression. cAMP/PKA was the major signaling pathway triggering the opposing effects of both treatment modes. Intermittent application of PTHrP represents an important novel means to improve chondrogenesis of MSCs and may be considered as a supporting clinical-treatment mode for MSC-based cartilage defect regeneration.Keywords
This publication has 53 references indexed in Scilit:
- Regeneration of articular cartilage by adipose tissue derived mesenchymal stem cells: Perspectives from stem cell biology and molecular medicineJournal of Cellular Physiology, 2012
- Proliferation as a Requirement for In Vitro Chondrogenesis of Human Mesenchymal Stem CellsStem Cells and Development, 2012
- Reduced Reactivation from Dormancy but Maintained Lineage Choice of Human Mesenchymal Stem Cells with Donor AgePLOS ONE, 2011
- Molecular basis of parathyroid hormone receptor signaling and trafficking: a family B GPCR paradigmCellular and Molecular Life Sciences, 2010
- Deleterious Effects of Intermittent Recombinant Parathyroid Hormone on Cartilage Formation in a Rabbit Microfracture Model: A Preliminary StudyHSS Journal®: The Musculoskeletal Journal of Hospital for Special Surgery, 2009
- Intermittent PTH stimulates periosteal bone formation by actions on post-mitotic preosteoblastsBone, 2009
- Contributions of parathyroid hormone (PTH)/PTH-related peptide receptor signaling pathways to the anabolic effect of PTH on boneBone, 2007
- Parathyroid hormone-related peptide (PTHrP) inhibits Runx2 expression through the PKA signaling pathwayExperimental Cell Research, 2004
- Differential regulation of type‐II and type‐X collagen synthesis by parathyroid hormone‐related protein in chick growth‐plate chondrocytesJournal of Orthopaedic Research, 1997
- Invitro and invivo antagonists against parathyroid hormone-related proteinBiochemical and Biophysical Research Communications, 1989